Seven vital questions about the RNA Covid-19 vaccines emerging from clinical trials
Preliminary data from phase III clinical trials has shown the Pfizer-BioNTech and Moderna Covid-19 vaccines to be more than 90% effective. They are the first vaccine candidates to produce such positive results, and this is great news.
These vaccines, unlike the vaccines we already use for other diseases, have been developed using ribonucleic acid (RNA) technology. So, how do they work, are they safe, and when will they be available?